Quantcast
Last updated on April 24, 2014 at 13:57 EDT

Latest Alimera Sciences Inc. Stories

2014-04-14 12:33:11

PDUFA goal date set for September 26, 2014 ATLANTA, April 14, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its recent resubmission of the New Drug Application (NDA) for ILUVIEN(®) has been acknowledged as received by the U.S. Food and Drug Administration (FDA) as a complete class 2 response to the...

2014-03-27 08:33:35

ATLANTA, March 27, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN(®) to the U.S. Food and Drug Administration (FDA). At this time, Alimera awaits the FDA's acceptance of the resubmission and a Prescription Drug User Fee Act (PDUFA) date. Alimera...

2014-02-28 08:25:09

ATLANTA, Feb. 28, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Cowen and Company 34(th) Annual Healthcare Conference on Wednesday, March 5, 2014 at 10:00 A.M. ET in Boston, MA. The presentation will be webcast live and will be...

2014-02-27 16:28:26

ILUVIEN® Revenue Growth in Europe Continues ATLANTA, Feb. 27, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2013. "This is an exciting time for Alimera. We made significant commercial progress with ILUVIEN® during the fourth...

2014-02-20 16:25:48

ATLANTA, Feb. 20, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2013 financial results after the market close on Thursday, February 27, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET. The conference call will be hosted...

2014-02-13 08:30:26

ATLANTA, Feb. 13, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Citi 2014 Global Healthcare Conference on Tuesday, February 25, 2014 at 1:50 P.M. ET in New York, NY. The presentation will be webcast live and will be available for...

2014-02-10 08:27:44

SMC advice follows positive NICE final guidance issued in November 2013 ATLANTA, Feb. 10, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Scottish Medicines Consortium (SMC), after completing its assessment and review of a simple patient access scheme, has accepted ILUVIEN® for restricted use within...

2014-02-03 08:27:58

ATLANTA, Feb. 3, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it closed its previously announced private placement of common stock on January 31, 2014. Gross proceeds from the offering were approximately $37.5 million. Proceeds from the private placement are expected to be used for general...

2014-01-28 08:29:12

ATLANTA, Jan. 28, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has obtained commitments from certain non-affiliated institutional investors to purchase approximately $37.5 million of its common stock in a private placement. Proceeds from the private placement are expected to be used for general...

2014-01-13 08:26:25

First NHS patient treated less than seven weeks following NICE published guidance ATLANTA, Jan. 13, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has begun shipping initial orders of ILUVIEN® to several United Kingdom National Health Service (NHS) facilities. Additionally, on January 10, 2014, the...